Warning letter
Eurosirel S.P.A: warning letter of Nov 20, 2024
FDA warning letter 690733 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 690733 |
|---|---|
| Company | Eurosirel S.P.A |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Nov 20, 2024 |
| Posted date | Nov 26, 2024 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.34, 211.22(a), 211.84(d)(1), 211.182, 211.188 |
| Inspection city | Cusago |
| Inspection start date | May 20, 2024 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: